3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
55
Carcinoma, Hepatocellular
54
Lung Neoplasms
32
Small Cell Lung Carcinoma
28
Neoplasms
25
Breast Neoplasms
20
Colorectal Neoplasms
18
Melanoma
15
Urinary Bladder Neoplasms
13
Triple Negative Breast Neoplasms
13
Carcinoma, Transitional Cell
13
Neoplasm Metastasis
12
Carcinoma, Renal Cell
12
Squamous Cell Carcinoma of Head and Neck
10
Prostatic Neoplasms
9
Uterine Cervical Neoplasms
8
Glioblastoma
8
Stomach Neoplasms
7
Endometrial Neoplasms
7
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Sarcoma
5
Pancreatic Neoplasms
5
Carcinoma, Neuroendocrine
5
Carcinoma, Merkel Cell
5
Liver Neoplasms
4
Kidney Neoplasms
4
Extensive Stage Lung Small Cell Carcinoma
4
Carcinoma
4
Brain Neoplasms
4
Interventions
pembrolizumab
1
enfortumab vedotin
1
atezolizumab
1
Immunotherapy
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle-invasive Bladder Cancer
×
atezolizumab
×
1 year
×
Clear all
NCT04660344
2026-03-27
IMvigor011
Hoffmann-La Roche
Phase 3
Active not recruiting
761 enrolled
1 FDA